RecruitingNCT06450067

Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World

Sponsor

Juventas Cell Therapy Ltd.

Enrollment

200 participants

Start Date

Jun 5, 2024

Study Type

OBSERVATIONAL

Conditions

B-cell Acute Lymphoblastic Leukemia

Summary

This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates inaticabtagene autoleucel — a CAR T-cell therapy that re-engineers a patient's own immune cells to attack B-cell leukemia — in adults with B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed or stopped responding to other treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia - Your doctor has determined you are eligible to receive this commercially available CAR T-cell treatment **You may NOT be eligible if...** - No specific exclusion criteria were listed for this study - Your doctor determines you are not suitable for this therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(10)

Peking University People's Hospital

Beijing, Beijing Municipality, China

Peking University Third Hospital

Beijing, Beijing Municipality, China

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University

Zhengzhou, Henan, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Qilu Hospital of Shandong university

Jinan, Shandong, China

Tongji Hospital of Tongji University

Shanghai, Shanghai Municipality, China

West China School of Medicine/West China Hospital of Sichuan University

Chengdu, Sichuan, China

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06450067

Related Trials

Study of Out of Specification for Tisagenlecleucel

NCT0409431153 locations

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

NCT045445921 location

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT0639510367 locations

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

NCT062087357 locations

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

NCT072230213 locations